gefitinib,erlotinib,Zorifertinib
Alpha Biopharma,AstraZeneca
['gefitinib', 'lung', 'nsclc', ' erlo', 'sclc']
randomized phase 3 study of first-line azd3759 (zorifertinib) versus gefitinib or erlotinib in egfr-mutant (egfrm+) non small-cell lung cancer (nsclc) with central nervous system (cns) metastasis. #asco23 #asco2023 #oncology #clinicaltrials 
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News